Sophia Ng1, Michael Y Ni, Vicky Jing Fang, Dennis Kai Ming Ip, Kwok-Hung Chan, Gabriel Matthew Leung, Joseph Sriyal Malik Peiris, Benjamin John Cowling. 1. From the *School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; †Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ; ‡Department of Microbiology, Li Ka Shing Faculty of Medicine; and §Centre for Influenza Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Abstract
BACKGROUND: Infections occurring among vaccinated persons (vaccine failures) are known to occur in vaccines with imperfect efficacy. Failures among vaccinated children who were infected with vaccine-matched influenza B virus strain have not been adequately characterized. METHODS: Taking advantage of a randomized controlled trial of trivalent seasonal influenza vaccine (TIV), the viral shedding and clinical symptoms associated with reverse transcriptase polymerase chain reaction-confirmed influenza B infection and serum hemaggluttination inhibiting antibody response to vaccine were compared between children 6 and 17 years receiving TIV andplacebo. RESULTS: Vaccine failures were observed to show lower antibody response to TIV compared with other vaccine recipients. We did not find any evidence that vaccination reduced the severity or duration of clinical symptoms of reverse transcriptase polymerase chain reaction-confirmed vaccine-matched influenza B infections. Vaccination was not observed to alter viral load or shedding duration. CONCLUSIONS: TIV was not observed to ameliorate clinical symptoms or viral shedding among vaccine failures compared with infected placebo recipients. Lower antibody response might have explained vaccine failure and also lack of effect in reducing clinical symptoms and viral shedding upon infection. Our results are based on a randomized controlled trial of split virus inactivated vaccine and may not be applicable to other vaccine types. Further studies in vaccine failure among children will be important in future vaccine development.
RCT Entities:
BACKGROUND: Infections occurring among vaccinated persons (vaccine failures) are known to occur in vaccines with imperfect efficacy. Failures among vaccinated children who were infected with vaccine-matched influenza B virus strain have not been adequately characterized. METHODS: Taking advantage of a randomized controlled trial of trivalent seasonal influenza vaccine (TIV), the viral shedding and clinical symptoms associated with reverse transcriptase polymerase chain reaction-confirmed influenza B infection and serum hemaggluttination inhibiting antibody response to vaccine were compared between children 6 and 17 years receiving TIV and placebo. RESULTS: Vaccine failures were observed to show lower antibody response to TIV compared with other vaccine recipients. We did not find any evidence that vaccination reduced the severity or duration of clinical symptoms of reverse transcriptase polymerase chain reaction-confirmed vaccine-matched influenza B infections. Vaccination was not observed to alter viral load or shedding duration. CONCLUSIONS: TIV was not observed to ameliorate clinical symptoms or viral shedding among vaccine failures compared with infected placebo recipients. Lower antibody response might have explained vaccine failure and also lack of effect in reducing clinical symptoms and viral shedding upon infection. Our results are based on a randomized controlled trial of split virus inactivated vaccine and may not be applicable to other vaccine types. Further studies in vaccine failure among children will be important in future vaccine development.
Authors: Suzanne E Ohmit; Joshua G Petrie; Rachel T Cross; Emileigh Johnson; Arnold S Monto Journal: J Infect Dis Date: 2011-10-12 Impact factor: 5.226
Authors: Danuta M Skowronski; Gaston De Serres; Natasha S Crowcroft; Naveed Z Janjua; Nicole Boulianne; Travis S Hottes; Laura C Rosella; James A Dickinson; Rodica Gilca; Pam Sethi; Najwa Ouhoummane; Donald J Willison; Isabelle Rouleau; Martin Petric; Kevin Fonseca; Steven J Drews; Anuradha Rebbapragada; Hugues Charest; Marie-Eve Hamelin; Guy Boivin; Jennifer L Gardy; Yan Li; Trijntje L Kwindt; David M Patrick; Robert C Brunham Journal: PLoS Med Date: 2010-04-06 Impact factor: 11.069
Authors: Robert B Couch; Robert L Atmar; Luis M Franco; John M Quarles; Janet Wells; Nancy Arden; Diane Niño; John W Belmont Journal: J Infect Dis Date: 2013-01-10 Impact factor: 5.226
Authors: Yong Ping Lin; Zi Feng Yang; Ying Liang; Zheng Tu Li; Helen S Bond; Huiying Chua; Ya Sha Luo; Yuan Chen; Ting Ting Chen; Wen Da Guan; Jimmy Chun Cheong Lai; Yu Lam Siu; Si Hua Pan; J S Malik Peiris; Benjamin J Cowling; Chris Ka Pun Mok Journal: BMC Infect Dis Date: 2016-11-04 Impact factor: 3.090
Authors: Huong Q McLean; Siri H Peterson; Jennifer P King; Jennifer K Meece; Edward A Belongia Journal: Influenza Other Respir Viruses Date: 2017-02-15 Impact factor: 4.380
Authors: Shannon E Brent; Eleanor Pullenayegum; Margaret L Russell; Mark Loeb Journal: Influenza Other Respir Viruses Date: 2019-11-08 Impact factor: 4.380